Skip to content

Continue Or Stop post-Stroke Antihypertensives Collaborative Study

A multicentre, prospective, randomised, open, blinded-endpoint study to assess whether existing antihypertensive therapy should be continued or discontinued within 24-hours of stroke onset and for the subsequent two weeks

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN89712435
Enrollment
3000
Registered
2010-05-28
Start date
2001-01-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Stroke Research Network

Interventions

Baseline investigations include blood pressure measurement using UA-767 monitor, modified Rankin Score, Barthel Index, National Institutes of Health Stroke Score and Oxfordshire Community Stroke Proje

Sponsors

University Hospitals of Leicester NHS Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged greater than or equal to 18 years, either sex 2. Stroke onset greater than or equal to 48 hours (for suspected stroke, onset time is last time patient was asymptomatic) 3. Clinical diagnosis of suspected stroke by neuroimaging before or after study entry to exclude non-stroke diagnoses and define stroke type 4. Currently receiving antihypertensive treatment and within 48 hours or last dose 5. Informed patient consent or relative/carer consent

Exclusion criteria

Exclusion criteria: 1. Hypertensive encephalopathy 2. Hypertension greater than 200/120 mmHg in association with intracerebral haemorrhage 3. Co-existing cardiac or vascular emergency 4. Contraindications to stopping antihypertensive therapy 5. Impaired conscious level 6. Dysphagia 7. Premorbid dependence 8. Co-existing life-threatening condition with life expectancy less than 6 months 9. Females of child-bearing potential 10. Non-stroke diagnoses

Design outcomes

Primary

MeasureTime frame
Death or dependancy (modified Rankin Score greater than 3) at 2 weeks post-randomisation

Secondary

MeasureTime frame
Early outcomes, measured at 2 weeks and 6 months: 1. Neurological deterioration 2. Functional status 3. Blood pressure changes from admission and discharge Late outcomes: 4. Death and dependency 5. Fatal and non-fatal stroke recurrence 6. Functional status 7. Health-related quality of life

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 31, 2026